Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

RSV shot uptake under the microscope: how many german babies get protected?

NCT ID NCT06824207

Knowledge-focused Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks how many infants in Germany receive nirsevimab, a long-acting antibody that helps protect against severe RSV disease. Researchers will survey parents of babies born during three RSV seasons (2024–2027) to measure immunization rates. The goal is to see how well the new universal recommendation is being followed and to guide future vaccination strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nirsevimab
What this could lead to
If successful, this study could help public health officials understand how well RSV immunization is reaching infants, potentially improving future vaccination programs.
What could go wrong
This is an observational study that only measures immunization rates, not health outcomes. It cannot prove whether nirsevimab prevents severe RSV disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,400 people

The number who actually took part.

Started

Jan 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study is conducted using various recruitment approaches, including but not limited to mailings, online panels, telephone contact, in person contact. The data i.e. respondents answers will be captured via an online questionnaire. The interviews will be conducted applying various methodologies e.g. self-completion (CAWI), assisted in person completion (F2F interviews), assisted telephone completion (CATI). The study will target a sample of parents of infants either born between April and September (catch-up cohort) or between October and March (in-season cohort). The study targets a representative distribution with regards to both aforementioned subgroups and regions. To achieve the primary objective in the representative sample of the German population of eligible parents, a needed sample size of approximately 2,400 participants in total per season is assessed. These are spread over a total of three waves per season, resulting in a sample size of 800 respondents per wave.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be a parent of an infant born between April 2024/25/26 and March 2025/26/27, respectively * Reside in Germany at the time of survey completion * Be at least 18 years old at the time of survey completion. * Agree with privacy policy and AE (Adverse Event) reporting requirements before proceeding with the survey. * Read and agree to the ICF (Informed Consent Form) by ticking a box before proceeding with the survey. Exclusion Criteria: * Participation in the study (= completed the survey) in a previous wave of the current season. Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus immunization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory syncytial virus immunization

Contacts and locations

Locations

  • Study site

    Germany, Germany, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.